Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Bayer disclosed that its Q2 earnings were inflated by transfer fees at its German football club Bayer Leverkusen.

Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

The US FDA has given accelerated approval to Jazz Pharma for Modeyso to treat adult and paediatric patients with diffuse midline glioma.

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

Fresenius has entered into a global licensing agreement for the commercialisation of Polpharma vedolizumab biosimilar candidate PB016.

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.